Dr. Kent Hoskins Appointed Oncology ...

Dr. Kent F. Hoskins

Claim this profile

University of Illinois

Studies Breast Cancer
Studies Breast cancer
11 reported clinical trials
20 drugs studied

Area of expertise

1Breast Cancer
Kent F. Hoskins has run 10 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
Stage IV
HER2 positive
2Breast Cancer
Kent F. Hoskins has run 3 trials for Breast cancer. Some of their research focus areas include:
HER2 negative
HER2 positive
ER positive

Affiliated Hospitals

Image of trial facility.
University Of Illinois
Image of trial facility.
University Of Illinois Cancer Center

Clinical Trials Kent F. Hoskins is currently running

Image of trial facility.

Tamoxifen

for Breast Cancer Risk Reduction

This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. Increasing breast density is a well established risk factor for breast cancer. Tamoxifen is a selective estrogen receptor modulator. It works by blocking the effects of the hormone estrogen in the breast. Tamoxifen has been shown to reduce breast density, even at reduced dosages, and is approved for the prevention of breast cancer.
Recruiting1 award Phase 2
Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria

More about Kent F. Hoskins

Clinical Trial Related1 year of experience running clinical trials · Led 11 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Kent F. Hoskins has experience with
  • Cyclophosphamide
  • Doxorubicin
  • Paclitaxel
  • Educational Video
  • Carboplatin
  • Regional Nodal XRT

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Kent F. Hoskins specialize in?
Is Kent F. Hoskins currently recruiting for clinical trials?
Are there any treatments that Kent F. Hoskins has studied deeply?
What is the best way to schedule an appointment with Kent F. Hoskins?
What is the office address of Kent F. Hoskins?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security